Benefits of Biosimilars

Biosimilars Expand Options for Patients and Providers.
Image of scientists
Overview
Benefits
Assessment
FAQ

With Meaningful Innovations in Value

Biosimilars will introduce genuine competition into an area of healthcare that until now has been largely unavailable. Competition can help reduce prices and help free up public funds to broaden overall access to healthcare. But, the real "value of biosimilars, first and foremost, needs to go to the patients."1,2

For biosimilars, the value proposition goes beyond the need for cost reduction relative to the innovator biologic drug and must incorporate the diverse needs of all of the key HCP stakeholders while maintaining clinical efficacy and safety outcomes similar to the originator biologic.

For Patients – The value of biosimilars will be the increased access to highly effective and often life-saving biological products due to a lower cost. Patients will experience value through potentially lower copayments and preferential tier placement.

For Providers – The value of biosimilars is based on interest in making certain their patients can afford the treatments they prescribe. Providers are looking toward the potential cost-savings for their patients as well as their practices.

For Payers – The value of biosimilars will be stimulated through the competitive pressures and the ability to induce price competition in the market place.

Patients - Payers - Providers

Although the US marketplace has just begun approving biosimilars, the perception of the value of biosimilars by stakeholders is clear.

  • Increased value by delivering highly similar clinical outcomes at a lower cost
  • Greater patient access to important biological therapies
  • Affordability for patients through potentially lower copayments
  • Cost savings to the global healthcare system

Invention is not the only innovation.

Apobiologix logo

2400 North Commerce Parkway,
Suite 300,
Weston, Florida 33326

855-276-7744

Email


  1. MMM-online.com, June 2015, page 35 accessed 11/19/2015
  2. Zelenetz AD, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011;9(suppl 4):S1-S22. P S3, Table 2.